Inovio Pharmaceuticals, Inc. is delaying the start of a Phase II/III trial for its COVID-19 vaccine candidate INO-4800 to address questions from the US Food and Drug Administration. The company announced a partial clinical trial hold for the vaccine on 28 September.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?